Literature DB >> 19140086

A six-colour flow cytometric method for simultaneous detection of cell phenotype and apoptosis of circulating endothelial cells.

S Mariucci1, B Rovati, S Chatzileontiadou, K Bencardino, M Manzoni, S Delfanti, M Danova.   

Abstract

Blood circulating endothelial cells (CECs), with their resting and activated subsets, (rCECs and aCECs) and circulating progenitors cells (CEPs) are two extremely rare cell populations that are important in tissue vascularization. Their number and function are modulated in diseases involving vascular injury, such as human tumours. Although a consensus on the phenotypic definition of endothelial cells, as well as on the optimal enumeration technique, is still lacking, the number of clinical studies based on assessment of these cells is rapidly expanding, as well as the analytical methods employed. The present study aimed to develop a rapid and sensitive flow cytometric method of quantifying and characterizing CECs (with both their subsets and the apoptotic fraction) and CEPs. We analysed peripheral blood samples from 21 subjects with a six-colour flow cytometric approach allowing detection of the cell phenotype of CECs and CEPs using a monoclonal antibodies panel and a dedicated gating strategy. Apoptotic CECs were detected with Annexin V and dead cells with 7-amino-actinomycin D staining. The described technique proved to be a new, reliable, tool increasing our knowledge of the biology of CECs and CEPs and can readily be applied in the study of many pathological conditions characterized by endothelial damage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19140086     DOI: 10.1080/00365510802673175

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  7 in total

1.  Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.

Authors:  Mariangela Manzoni; Sara Mariucci; Sara Delfanti; Bianca Rovati; Monica Ronzoni; Fotios Loupakis; Silvia Brugnatelli; Carmine Tinelli; Eugenio Villa; Alfredo Falcone; Marco Danova
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-15       Impact factor: 4.553

Review 2.  Human vascular endothelial cells: a model system for studying vascular inflammation in diabetes and atherosclerosis.

Authors:  Duygu Onat; David Brillon; Paolo C Colombo; Ann Marie Schmidt
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

3.  Isolation of a circulating CD45-, CD34dim cell population and validation of their endothelial phenotype.

Authors:  Margaret M Tropea; Bonnie J A Harper; Grace M Graninger; Terry M Phillips; Gabriela Ferreyra; Howard S Mostowski; Robert L Danner; Anthony F Suffredini; Michael A Solomon
Journal:  Thromb Haemost       Date:  2014-07-24       Impact factor: 5.249

4.  Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy.

Authors:  B Rovati; S Mariucci; S Delfanti; D Grasso; C Tinelli; C Torre; M De Amici; P Pedrazzoli
Journal:  Cell Oncol (Dordr)       Date:  2016-01-14       Impact factor: 6.730

5.  Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion.

Authors:  Elisa Tinazzi; Marzia Dolcino; Antonio Puccetti; Antonella Rigo; Ruggero Beri; Maria Teresa Valenti; Roberto Corrocher; Claudio Lunardi
Journal:  Arthritis Res Ther       Date:  2010-07-07       Impact factor: 5.156

Review 6.  Comprehensive phenotyping of endothelial cells using flow cytometry 2: Human.

Authors:  Dillon Grant; Nicholas Wanner; Matthew Frimel; Serpil Erzurum; Kewal Asosingh
Journal:  Cytometry A       Date:  2020-12-23       Impact factor: 4.714

Review 7.  Circulating endothelial cells and chronic kidney disease.

Authors:  Kunying Zhang; Fang Yin; Lin Lin
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.